You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Patent: 9,993,568


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,993,568
Title:Compounds comprising self-immolative group
Abstract: Provided are methods of use of compounds comprising a self-immolative group, which compounds may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
Inventor(s): Kim; Yong Zu (Daejeon, KR), Park; Tae Kyo (Daejeon, KR), Woo; Sung Ho (Daejeon, KR), Kim; Sun Young (Daejeon, KR), Cho; Jong Un (Daejeon, KR), Jung; Doo Hwan (Daejeon, KR), Min; Ji Young (Daejeon, KR), Lee; Hyang Sook (Daejeon, KR), Park; Yun Hee (Daejeon, KR), Ryu; Jeong Hee (Daejeon, KR), Oh; Kyu Man (Daejeon, KR), Oh; Yeong Soo (Daejeon, KR), Chae; Jeiwook (Daejeon, KR), Song; Ho Young (Daejeon, KR), Chung; Chul-Woong (Daejeon, KR), Yang; Jeon (Daejeon, KR)
Assignee: LegoChem Biosciences, Inc. (Daejeon, KR)
Application Number:14/898,932
Patent Claims:see list of patent claims

Details for Patent 9,993,568

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 12/22/1994 ⤷  Try a Trial 2034-05-28
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2034-05-28
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 05/12/1998 ⤷  Try a Trial 2034-05-28
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 01/02/2003 ⤷  Try a Trial 2034-05-28
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab For Injection 103770 06/19/1998 ⤷  Try a Trial 2034-05-28
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab Injection 103770 07/23/2004 ⤷  Try a Trial 2034-05-28
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 08/24/1998 ⤷  Try a Trial 2034-05-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.